SE2050559A1 - PD-1 as a predictive marker for therapy in cancer - Google Patents

PD-1 as a predictive marker for therapy in cancer

Info

Publication number
SE2050559A1
SE2050559A1 SE2050559A SE2050559A SE2050559A1 SE 2050559 A1 SE2050559 A1 SE 2050559A1 SE 2050559 A SE2050559 A SE 2050559A SE 2050559 A SE2050559 A SE 2050559A SE 2050559 A1 SE2050559 A1 SE 2050559A1
Authority
SE
Sweden
Prior art keywords
therapy
cancer
predictive marker
determining
breast cancer
Prior art date
Application number
SE2050559A
Inventor
Tullberg Axel Stenmark
Erik Holmberg
Per Karlsson
Original Assignee
Khs Biomedinvent Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khs Biomedinvent Ab filed Critical Khs Biomedinvent Ab
Priority to SE2050559A priority Critical patent/SE2050559A1/en
Priority to AU2021272986A priority patent/AU2021272986A1/en
Priority to CA3183417A priority patent/CA3183417A1/en
Priority to PCT/US2021/032080 priority patent/WO2021231641A1/en
Priority to EP21803206.8A priority patent/EP4149616A1/en
Priority to US17/998,334 priority patent/US20230375549A1/en
Publication of SE2050559A1 publication Critical patent/SE2050559A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

There is provided a method for treating breast cancer comprising the steps:a) obtaining a tissue sample of a tumour from a breast cancer patient, b) determining the expression level of PD-1 in the sample,c) determining that the expression level is below a threshold level,d) providing intensified treatment as radiotherapy treatment, systemic therapy or mastectomy to the patient.
SE2050559A 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer SE2050559A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer
AU2021272986A AU2021272986A1 (en) 2020-05-13 2021-05-12 PD-1 as a predictive marker for therapy in cancer
CA3183417A CA3183417A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer
PCT/US2021/032080 WO2021231641A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer
EP21803206.8A EP4149616A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer
US17/998,334 US20230375549A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer

Publications (1)

Publication Number Publication Date
SE2050559A1 true SE2050559A1 (en) 2021-11-14

Family

ID=78816986

Family Applications (1)

Application Number Title Priority Date Filing Date
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer

Country Status (1)

Country Link
SE (1) SE2050559A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145493A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2017140826A1 (en) * 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
WO2018160841A1 (en) * 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018191660A1 (en) * 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145493A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2017140826A1 (en) * 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
WO2018160841A1 (en) * 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018191660A1 (en) * 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lu L et al., "Elevated T cell activation score is associated with improved survival of breast cancer", Breast Cancer Res Treat, 2017, 164(3):689-696 *
Yeong J et al., "Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer", J Immunother Cancer, 2019, 7:34 *

Similar Documents

Publication Publication Date Title
ES2721639T3 (en) Method for diagnosis, prognosis and treatment of breast cancer metastasis
MX2021001857A (en) Diagnostic and therapeutic methods for the treatment of breast cancer.
BR112019023409A2 (en) METHODS FOR TREATING CANCER IN A PATIENT AND A HEMATOLOGICAL MALIGNITY, FOR EXPANDING TUMOR INFILTRANT LYMPHOCYTES, PERIPHERAL BLOOD LYMPHOCYTES AND INFILTRANT SPRAY LYMPHOCYTES, PROCEDURE FOR THE PREPARATION OF A POPULATION IN THE MANUFACTURE OF A POPULATION OF TUMOR INFILTRANT LYMPHOCYTES.
Sedlmayer et al. Boost IORT in breast cancer: body of evidence
MX2019006331A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens.
WO2018183817A3 (en) Tumor burden as measured by cell free dna
EA202092113A1 (en) METHOD FOR PRODUCING P300 AND / OR CBP MODULATORS
SE2050559A1 (en) PD-1 as a predictive marker for therapy in cancer
MX2021003214A (en) Therapeutic and diagnostic methods for bladder cancer.
Pan et al. A novel approach of INTRABEAM intraoperative radiotherapy for nipple-sparing mastectomy with breast reconstruction
MX2022011050A (en) Anti-cd36 antibodies and their use to treat cancer.
MX2020013883A (en) Oncology treatments using zinc agents.
RU2624367C1 (en) Method for selection of locoregional radiation therapy volume after breast cancer surgery
EP4138811A4 (en) Composition, kit and method for diagnosis and treatment of prostate cancer
MX2022013914A (en) Method for treating pancreatic cancer.
Marinova et al. Radiotherapy after Breast-Preserving Surgery for Early Breast Cancer-Basic Principles and Our Experience
MX2021005189A (en) Use of tivozanib to treat subjects with refractory cancer.
Chuang et al. Post-Mastectomy Radiation Therapy in Stage II N1 Breast Cancer Patients Is Associated with Improved Survival with Different Sub-Type
IL308684A (en) Methods of treating breast cancer
Parks et al. THE ROLE OF THE ANDROGEN RECEPTOR IN PRIMARY BREAST CANCER IN OLDER WOMEN
RU2734719C1 (en) Method for prediction of occurrence of local recurrences in postoperative period in patients with locally advanced breast cancer
FI130157B (en) Method for determining whether a subject is at risk of dying from breast cancer
Liss et al. Decline of Cosmetic Outcomes Following Accelerated Partial Breast Irradiation (APBI) Using Intensity Modulated Radiation Therapy (IMRT): Results of a Single-Institution Prospective Clinical Trial
Li et al. One-year Follow-up of Volumetric-modulated Arc Therapy for Treating Chest Wall and Regional Nodes in Locally Advanced Breast Cancer
GB202006474D0 (en) Method of treatment of cancer or tumour

Legal Events

Date Code Title Description
NAV Patent application has lapsed